Vanda Pharmaceuticals VNDA
NASDAQ VNDA
$4.63 -0.18 (-3.74%)
At close: Oct 2, 2026 · 4:00 PM EDT

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2010 - 2026)

Updated

Vanda Pharmaceuticals' Liabilities and Shareholders Equity was $412.47 million in Q2 2026, down 34.0% from $624.75 million a year earlier and down 4.9% from the prior quarter.

Analysis

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Vanda Pharmaceuticals came in at $488.95 million, down 25.5% from FY2024.

  • Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -1.7% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $656.2 million in FY2024 (+1.2%), $648.44 million in FY2023 (+2.2%), $634.25 million in FY2022 (+6.8%) and $593.79 million in FY2021 (+11.3%).
  • The Q2 2026 figure marks the lowest quarterly Liabilities and Shareholders Equity since Q2 2019.
  • Compared with a year earlier, Liabilities and Shareholders Equity has declined for six straight quarters, with an average decline of 12.9% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q3 2021 (growth of 12.4%); the worst was Q2 2026 (a decline of 34.0%).
  • Per Business Quant data, VNDA's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $433.53 million (Q1 2026), $488.95 million (Q4 2025) and $601.14 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 142.28 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 201.06 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 135.12 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 129.80 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 122.03 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 115.83 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 95.64 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 49.36 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 201.13 Bn
10 Vanda Pharmaceuticals 279.91 Mn -650.03 Mn 46.97 Mn 412.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 412.47 Mn
Mar 31, 2026 433.53 Mn
Dec 31, 2025 488.95 Mn
Sep 30, 2025 601.14 Mn
Jun 30, 2025 624.75 Mn
Mar 31, 2025 631.94 Mn
Dec 31, 2024 656.20 Mn
Sep 30, 2024 645.12 Mn
Jun 30, 2024 651.37 Mn
Mar 31, 2024 652.68 Mn
Dec 31, 2023 648.44 Mn
Sep 30, 2023 641.61 Mn
Jun 30, 2023 641.68 Mn
Mar 31, 2023 644.53 Mn
Dec 31, 2022 634.25 Mn
Sep 30, 2022 621.79 Mn
Jun 30, 2022 609.10 Mn
Mar 31, 2022 603.56 Mn
Dec 31, 2021 593.79 Mn
Sep 30, 2021 579.77 Mn
API Access

Vanda Pharmaceuticals Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=VNDA&period=max&api_key=YOUR_API_KEY